GLP-1 receptor agonists may have beneficial effects against Alzheimers, psychiatric and addiction disorders, but early data are “not sufficient to establish an indication,” a speaker reported.At the ...
Q3 2025 Management View David Meeker, Chairman, President & CEO, highlighted "strong growth and continued momentum during the third quarter as we prepare to launch IMCIVREE in acquired hypothalamic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback